A study of three immunotherapy drugs for advanced melanoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of three immunotherapy drugs (fianlimab, cemiplimab, and ipilimumab) for people with advanced melanoma that has stopped responding to previous PD-1/PD-L1 treatment. It aims to see if this new combination can help shrink or control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your melanoma must be advanced (stage III or IV) and cannot be surgically removed, or it has spread to other parts of the body.
- You must have already received treatment with a PD-1/PD-L1 immunotherapy drug, and your cancer grew or came back on that treatment.
- You need to be able to get a biopsy or have a stored tumor sample from a previous biopsy.
- Your overall health should be good enough to carry out daily activities (ECOG score 0 or 1).
- You must have at least one tumor that can be measured on scans.
- You cannot have certain types of melanoma, like uveal melanoma, or untreated brain metastases.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (IMC-F106C) combined with standard treatments against the usual nivolumab-based therapy for people with advanced melanoma who have not been treated before. It's for people who carry a specific immune system marker (HLA-A*02:01) and are in fairly good health.
This trial tests a combination of two drugs (iparomlimab and tuvonralimab) plus bevacizumab for people with advanced melanoma whose cancer got worse after prior immunotherapy. The goal is to see if this new combination can help when standard treatments stop working.
This study tests whether giving two immunotherapy drugs (fianlimab and cemiplimab) before surgery helps treat melanoma that has spread to nearby lymph nodes or a small number of other sites. The goal is to shrink tumors and improve surgical outcomes.
This trial tests a combination of daily low-dose cyclophosphamide (a chemotherapy pill) and pembrolizumab (an immunotherapy) in people with advanced melanoma that has stopped responding to prior immunotherapy. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial is testing a combination of two immunotherapy drugs (anti-LAG-3 and anti-PD-1 antibodies) to see if they work better than standard treatment for people with advanced melanoma that hasn't been treated before. It may be an option if you have not yet received any systemic therapy for your melanoma.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
Hear when a new Advanced Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.